The present invention relates to an algal extract comprising sulphated and non-sulphated polyanionic polysaccharides, to a method for preparing an algal extract as well as to its therapeutic and prophylactic applications.

Use of a seaweed blend to modify gastrointestinal (GI) microbiota of an animal host. Modifying the GI microbiota may comprise modifying a community of bacteria, wherein the community of bacteria comprises Firmicutes and Bacteriodetes and the seaweed blend modifies the ratio of Firmicutes to Bacteriodetes, such as increasing the ratio of Firmicutes to Bacteriodetes. Further, the seaweed blend modifies specific families of commensal bacteria families including Ruminococceae and Lachnospiraceae within the Phyla Firmicutes. The seaweed blend may comprise (i) 65-80 wt % Ulva; (ii) 3-8 wt % Gracilaria; and (iii) 15-25 wt % Sargassum and/or Ascophyllum.

This disclosure relates to new compositions and methods for treating skin conditions as a result of sun damage. In one embodiment this disclosure pertains to new compositions for treating or preventing sunburns, skin damage, and/or harm from radiation, such as UV radiation.

This disclosure relates to new compositions and methods for treating skin conditions as a result of sun damage. In one embodiment this disclosure pertains to new compositions for treating or preventing sunburns, skin damage, and/or harm from radiation, such as UV radiation.

A composition comprising a concentration of total lipids, wherein at least 20% of the total lipids concentration by weight % comprises a polar lipids fraction, with greater than about 30% by weight % of the polar lipids fraction comprising glycolipids, and wherein the composition comprises no greater than 4% of its weight % as chlorophyll concentration, and formulations and medical compositions including the lipids-containing composition.

A composition comprising a concentration of total lipids, wherein at least 20% of the total lipids concentration by weight % comprises a polar lipids fraction, with greater than about 30% by weight % of the polar lipids fraction comprising glycolipids, and wherein the composition comprises no greater than 4% of its weight % as chlorophyll concentration, and formulations and medical compositions including the lipids-containing composition.

The present invention provides Dunaliella alga, and extracts thereof, comprising increased levels of 9-cis-β-carotene and/or increased levels of colourless carotenoids; and/or increased levels of α-carotene, to processes for producing such Dunaliella alga, and to uses thereof.

The present invention provides Dunaliella alga, and extracts thereof, comprising increased levels of 9-cis-β-carotene and/or increased levels of colourless carotenoids; and/or increased levels of α-carotene, to processes for producing such Dunaliella alga, and to uses thereof.

The present invention is concerned with a photosynthetic scaffold that delivers oxygen and its uses for tissue engineering and the treatment of ischemia.

The present invention is concerned with a photosynthetic scaffold that delivers oxygen and its uses for tissue engineering and the treatment of ischemia.